Accelerated Upstream Process Development Of Adeno-Associated Viruses From High‐Throughput Systems To Clinical Scale

When your AAV program faces cost of goods exceeding $1 million per dose and development timelines stretching 12 to 24 months, every process decision carries enormous weight. Balancing transfection reagent levels, cell density, and full capsid yield across scales is one of the most operationally complex challenges in gene therapy manufacturing, and the gap between bench-scale screening and commercial production remains a persistent obstacle.

This case study details how a high-throughput Design of Experiments approach in the Ambr 15 system accelerated AAV9 process development, identifying an optimized transfection condition within two months. The key finding: setting viable cell density at 2.3 x 10⁶ cells/mL and DNA at 0.25 µg per 10⁶ cells delivered the best balance of specific productivity and full capsid content, achieving a 60% reduction in COGs per dose compared to industry benchmarks.

Critically, this work goes beyond small-scale optimization. A bridging study established that viral genome titer correlates with the combined effect of agitation and airflow, enabling direct translation of operating conditions to a 2,000 L single-use bioreactor. Viral genome titers of 6.2 x 10¹⁰ vg/mL at 2,000 L were statistically comparable to Ambr 15 results, across a greater than 100,000-fold increase in volume. Full capsid percentage, residual host cell DNA, and process reproducibility all held consistent across scales.

If you are designing or scaling an AAV upstream process, the engineering strategies and scale-up data presented here offer a practical framework for reducing risk and cost. Download now to apply these findings to your own AAV manufacturing development program.